Mason McCrury, Kennith Swafford, Sydnye L Shuttleworth, Syed Hassan Mehdi, Baku Acharya, Debasmita Saha, Kevin Naceanceno, Stephanie D Byrum, Aaron J Storey, Ying-Zhi Xu, Claire Doshier, Vijay Patel, Ginell R Post, Annick De Loose, Analiz Rodriguez, Leonard D Shultz, Fenghuang Zhan, Donghoon Yoon, Brendan Frett, Samantha Kendrick
Expression of the serine/threonine kinase NEK2 is essential for entry into mitosis via its role in facilitating centrosome separation. Its overactivity can lead to tumorigenesis and drug resistance through the activation of several oncogenic pathways including AKT. While the cancer-enabling activities of NEK2 are documented in many malignancies, including correlations with poor survival in myeloma, breast, and non-small cell lung cancer, little is known about the role of NEK2 in lymphoma. Here, in tumors from patients with diffuse large B cell lymphoma (DLBCL), the most common, aggressive non-Hodgkin lymphoma, we found a high abundance of NEK2 mRNA and protein associated with an inferior overall survival...
October 11, 2023: Molecular Cancer Therapeutics